Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by coyote13on Feb 10, 2015 10:01am
233 Views
Post# 23413782

RE:Moran insider buying

RE:Moran insider buyingAbility to trade for Moran et al means " no material undisclosed information". A bit surprising
given PLI  is 42 days into its Q4 financial reporting process. In most public co's, that would lock down ones ability to transact. Be that as it may, any insights/ thoughts from those in the know about the status of the outstanding catalysts from H2/2014. Presumably the ones from  FD's list have not moved ahead. Again somewhat surprising given Q3 CC comments from PLI.

Tic toc tic toc.

Coyote13




Bullboard Posts